The DOI matches its Crossref record; 22 of the 24 references it cites were found in a registry or an index; none of the 19 sources its claims cite is checked for support yet.
In vitro comparative quality assessment of different brands of norfloxacin tablets available in Jimma, Southwest Ethiopia
Open accessAbstract
BACKGROUND: Pharmaceuticals play a pivotal role in maintaining human health and promoting well-being. However, safety, efficacy, and quality of the drugs should be ascertained to provide a desired pharmacological effect. AIM: The aim of the present study was to determine the quality as well as the physicochemical equivalence of nine brands of norfloxacin tablets marketed in Jimma, Ethiopia. METHODS: Nine norfloxacin brands were subjected to in vitro tests associated with quality of tablet dosage form, and the tests were conducted according to procedures described in the United States Pharmacopeia (USP). RESULTS: This study indicated that all brands of norfloxacin complied with the USP for uniformity of weight, friability, hardness, and assay of active ingredient. However, two of the nine brands evaluated failed to release 80% of their drug contents within 30 minutes as outlined in the USP. Correspondingly, all of the brands studied were within the specification for hardness test. Furthermore, different dissolution profile comparison methods have proven the similarity in dissolution profile of Negaflox and Norcin with the comparator product (Trizolin). Mathematical models-dependent approaches have shown that the drug release data fit well to the Weibull release model. CONCLUSION: The physicochemical evaluation showed that all the norfloxacin brands met the quality specification with respect to uniformity of weight, hardness, friability, and assay. With regard to dissolution test, two brands of norfloxacin were found to be out of the specified pharmacopeial requirement. The study also revealed the similarity in the dissolution profile of two brands of norfloxacin with the comparator product.
Overview
CoChat Summary
## TL;DR
This in vitro study compared nine 400 mg norfloxacin tablet brands marketed in Jimma, Ethiopia using USP-based quality tests. All brands passed weight variation, hardness, friability, and assay criteria, but two brands failed the USP dissolution requirement and only three brands (N1, N5, N7) were judged interchangeable with the comparator based on dissolution-profile comparisons.
## Key findings
- All nine brands met USP specifications for uniformity of weight, hardness, friability, and assay of active ingredient.
- Two of nine brands failed the USP dissolution criterion of releasing not less than 80% within 30 minutes: N3 (77.05%) and N8 (74.45%).
- In dissolution-profile comparison, N1, N5, and N7 were similar to the comparator (N9) by multiple metrics: f2 > 50, f1 < 15, and DE differences within ±10%.
- The authors report that drug-release data for all brands fit best to the Weibull model.
## Methods
- Design/sample: Laboratory-based comparative in vitro evaluation of nine norfloxacin tablet brands (all 400 mg) purchased from licensed retail outlets and a hospital pharmacy in Jimma, Ethiopia; one marketed product (N9) served as the comparator because the innovator product was unavailable.
- Tests performed: USP-based weight variation (20 tablets/brand), friability (20 tablets/brand), hardness (10 tablets/brand), assay by HPLC, and dissolution testing (6 tablets/brand).
- Analysis: Descriptive comparison plus one-way ANOVA (and Dunnett’s test for comparator comparisons), f1/f2 similarity factors, dissolution efficiency (DE), and fitting of release data to zero-order, first-order, Higuchi, Hixson–Crowell, and Weibull models.
## Limitations
- The paper does not state formal study limitations.
- Evident from the text: this was an in vitro study only, so it does not directly measure in vivo bioequivalence or clinical outcomes.
- Evident from the text: the comparator was not the innovator product; it was a marketed product selected because the innovator was unavailable in the Ethiopian market.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 0 Not valid · 18 Not checked · 19 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“tablet hardness ranged from 79.06 N for brand N2 to 188.79 N for brand N5”
§ In vitro comparative quality assessment of different brands of norfloxacin tablets available in Jimma, Southwest Ethiopia > Results and discussion > Hardness test
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“brands N1, N2, N5, N6, N7, and N9 released greater than 50% drug within 10 minutes.”
§ In vitro comparative quality assessment of different brands of norfloxacin tablets available in Jimma, Southwest Ethiopia > Results and discussion > Dissolution studies
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“out of nine brands of norfloxacin tablets analyzed, seven brands passed the single point dissolution test specification of USP-2015”
§ In vitro comparative quality assessment of different brands of norfloxacin tablets available in Jimma, Southwest Ethiopia > Results and discussion > Dissolution studies
What the sources say
- Not matchedcites [23]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“N9, N1, N7, and N5 had the highest DE of 83.93%, 79.34%, 79.62%, and 78.08%, respectively”
§ In vitro comparative quality assessment of different brands of norfloxacin tablets available in Jimma, Southwest Ethiopia > Results and discussion > Dissolution profile comparison
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the comparator product (N9) tablet released the highest (83.72%) amount of the drug at 10 minutes.”
§ In vitro comparative quality assessment of different brands of norfloxacin tablets available in Jimma, Southwest Ethiopia > Results and discussion > Dissolution studies
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
19 more claims
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 10
- The quote only partly states this claim. 3
- Probably not a substantial claim. 3
Citations
Cites
Modeling and comparison of dissolution profiles
Costa, P., & Sousa Lobo, J. M. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00095-1 · Cited by 5,509 · cited 2×
“Different kinetic equations are given below.(27)”
MethodSubstandard drugs: a potential crisis for public health
Johnston, A., & Holt, D. W. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12298 · Cited by 270 · cited 2×
“Furthermore, the consumption of poor quality drugs is characterized by numerous consequences including treatment failure, drug resistance, increased morbidity and mortality.(14) Similarly, the absence of strong drug regulatory authorities and poor quality control practices in some countries have resulted in the availa…”
BackgroundAnderson, N. H., Bauer, M., Boussac, N., Khan-Malek, R., Munden, P., & Sardaro, M. (1998) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(98)00011-9 · Cited by 246 · cited 1×
“As reported by Anderson et al, the reference and the test products can be said to be equivalent if the difference between their dissolution efficiencies is within appropriate limits (±10%).(35) Based on this requirement, products N1, N5, and N7 are equivalent to brand N9 (comparator) as difference of % (test product –…”
BackgroundEffect of compaction pressure on the dissolution efficiency of some direct compression systems.
Khan, K. A., & Rhodes, C. T. (1972) · PubMed · Cited by 183
Kayumba, P. C., Risha, P., Shewiyo, D. H., Msami, A., Masuki, G., Ameye, D., Vergote, G. J., Ntawukuliryayo, J. D., Remon, J. P., & Vervaet, C. (2004) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2004.00568.x · Cited by 58 · cited 1×
“Similarly, the absence of strong drug regulatory authorities and poor quality control practices in some countries have resulted in the availability of poor-quality drugs.(16,17) A study conducted by WHO by reviewing published papers of 88 of the 194 WHO Member States found that from total 48,218 samples tested, 11.”
BackgroundSuleman, S., Zeleke, G., Waktola, H. D., Mekonnen, Z., Duchateau, L., Levecke, B., Vercruysse, J., D’Hondt, M., Wynendaele, E., & Spiegeleer, B. M. J. D. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003345 · Cited by 57 · cited 1×
“3% of the sampled medicines did not fulfilled pharmacopoeial quality specifications.(21) These facts directed all concerned parties to conduct quality assessment studies on available drug products circulating in the market to expose substandard drug products.”
BackgroundSelf-citationCórdoba-Borrego, M., Córdoba-Díaz, M., & Córdoba-Díaz, D. (1999) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(98)00037-5 · Cited by 55
Adegbolagun, O. A., Olalade, O. A., & Osumah, S. E. (2007) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v6i3.14654 · Cited by 48 · cited 1×
“However, the availability of multisource drugs have been accompanied by the widespread distribution of counterfeit and substandard drug products.(13) This is a serious public health problem that is significantly higher in poor and emerging economies.”
BackgroundRao, R. N., & Nagaraju, V. (2004) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2003.11.009 · Cited by 46 · cited 1×
“This drug is chemically known as 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)–3-quinolinecarboxylicacid(1,2) and commonly prescribed for the treatment of urinary, respiratory, and gastrointestinal tracts infections.(4) It is also active against clinically relevant pathogens responsible for causing sexually tra…”
BackgroundRole of newer fluoroquinolones in lower respiratory tract infections
Lode, H. M. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf024 · Cited by 45 · cited 1×
“It is also active against clinically relevant pathogens responsible for causing sexually transmitted diseases, sinuses, and prostate infections.(5,6) Pharmaceuticals play a pivotal role in maintaining human health and promoting well-being.”
Background
Cited by
Mekonnen, B. A., Yizengaw, M. G., & Worku, M. C. (2024) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2024.2375267 · Cited by 60
“Antihypertensive medicines are also exposed to this problem (Chikowe et al., 2015; Hambisa et al., 2019; Kitutu, 2015; Koech et al., 2020; Njeri et al., 2021; Oli et al., 2020; Osei-Safo et al., 2014; Ozawa et al., 2018; Patricia et al., 2019; Visser et al., 2015).”
BackgroundInfluentialJuhász, Á., Ungor, D., Berta, K., et al. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.115405 · Cited by 35
El‐Sabban, H. A., Ali, A. B. M., Alhuzaymi, T. M., Kadhum, A. A. H., Hasan, M., Diab, M. A., Atamuratova, Z. A., Saitov, E., & Ko, Y. G. (2025) · Journal of Water Process Engineering · doi:10.1016/j.jwpe.2025.107131 · Cited by 34
Substandard and falsified antimicrobials in selected east African countries: A systematic review
Tegegne, A. A., Bekele, A., Hasen, G., Mekasha, Y. T., Hassen, H. K., Özalp, Y., & Suleman, S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0295956 · Cited by 40
Self-citationPress-Coated Aceclofenac Tablets for Pulsatile Drug Delivery: Formulation and In Vitro Evaluations
Rashid, R., Zaman, M., Ahmad, M., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15030326 · Cited by 22
Metadata
- Authors
- Hambisa, S., Belew, S., & Suleman, S.
- Affiliations
- Jimma University (ET)
- Corresponding author
- Hambisa, Solomon
- Venue
- Drug Design Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2019-04
- Volume
- Volume 13
- Pages
- 1241-1249
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC6475098
- OpenAlex
- W2940268474
- Cited by
- 30
- References
- 24
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 6 · 2020: 3
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Jimma University
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Physical Sciences › Chemistry › Analytical Chemistry › Analytical Methods in Pharmaceuticals
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- drug quality assessment, dissolution profile, weight uniformity, friability, tablet hardness, generic drug quality, Jimma, Ethiopia
- MeSH terms
- Anti-Bacterial Agents, Ethiopia, Kinetics, Norfloxacin, Quality Control, Tablets, Drug Liberation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vitro comparative quality assessment of different brands of norfloxacin tablets available in Jimma, Southwest Ethiopia. https://app.cochat.ai/papers/10.2147/dddt.s189524
- The paper
- Hambisa, S., Belew, S., & Suleman, S. (2019). In vitro comparative quality assessment of different brands of norfloxacin tablets available in Jimma, Southwest Ethiopia. Drug Design Development and Therapy. https://doi.org/10.2147/dddt.s189524
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.